HAART has been shown to effectively reduce the morbidity and mortality associated with HIV infection [1] [2] [3] [4] [5] . Accompanying the success of this therapy, however, is the concern about increases in or return to behaviors associated with HIV transmission in high-risk populations because of the improved health status of those who are HIV-infected and because of complacency
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This study identifies factors associated with high-risk sexual and drug injection behaviors among human immunodeficiency virus (HIV)-infected injection drug users (IDUs) after initiation of highly active antiretroviral therapy (HAART). Participants of a large cohort study of IDUs in
HAART has been shown to effectively reduce the morbidity and mortality associated with HIV infection [1] [2] [3] [4] [5] . Accompanying the success of this therapy, however, is the concern about increases in or return to behaviors associated with HIV transmission in high-risk populations because of the improved health status of those who are HIV-infected and because of complacency about safe sexual and injection practices among both HIV-infected and HIV-uninfected individuals.
Recent reports indicate increases in high-risk sexual behaviors, incidence of anal/rectal gonorrhea, and HIV seroincidence among homosexual and bisexual populations in the HAART era [6, 7] . Other studies have reported that decreased concern about HIV infection and diminished caution regarding sexual and drug use behaviors are associated with use of new anti-HIV therapies [8] [9] [10] [11] [12] [13] . A recent study found HAART use among homosexual men to be significantly associated with an increased rate of high-risk sexual behaviors [14] . Few studies, however, have reported on risk behaviors among injection drug users (IDUs) after initiation of HAART. A study of HIV-infected IDUs in France showed a significant association between HAART use and decreased sexual risk [15] . However, a study by Vlahov et al. [16] among IDUs in Baltimore reported increased sexual activity, including unprotected sexual intercourse, among HAART recipients during the 6 months after HAART initiation, compared with declines in these activities among subjects who did not initiate HAART. Initiation of HAART however, was not associated with resumption of drug injection or needle sharing.
The current analysis extends the work conducted by Vlahov et al. [16] in 2 ways. First, we evaluate changes in sexual and drug injection behaviors in a larger sample of the same cohort of IDUs up to 5 years after HAART initiation. Second, we investigate the effects of immunologic response on high-risk sexual and drug injection behaviors after initiation of HAART.
METHODS
Study population.
The AIDS Link to Intravenous Experiences (ALIVE) Study is a prospective cohort study of the natural history of and risk factors for HIV infection among IDUs in Baltimore, Maryland. The study methodology has been described elsewhere [17] . Briefly, recruitment was conducted in 1988-1989 and in 1994, and a total of 3360 participants were enrolled. Eligibility criteria included being у18 years old, reporting a history of illicit drug injection within the previous 11 years, and being AIDS-free at the time of enrollment. All HIV-seropositive participants and a sample of HIV-seronegative participants were asked to enroll in the follow-up study. Semiannual follow-up visits consisted of an interview, a complete physical examination, and venipuncture for collection of a blood sample. Data were collected on sexual and drug use behaviors through questionnaires administered by trained study interviewers and audio computer-assisted self-interview. Starting in 1995, participants were asked about initiation of therapy with any anti-HIV medications in the 6-month period prior to the interview. At each semiannual visit, HIV-seropositive participants were given their CD4 + cell count from the previous visit. However, data on HIV RNA levels were not available, because laboratory tests for HIV RNA were not conducted until 2001. HIV infection was detected using ELISA (Genetic Systems), with confirmation of positive test results by Western blot assay (DuPont). CD4 + cell counts were determined by flow cytometry, and HIV RNA levels were determined with Amplicor HIV Monitor Test (Roche Diagnostic Systems) with a lower limit of quantification of 50 RNA copies/mL. The study was approved by the Committee on Human Research at Johns Hopkins Bloomberg School of Public Health.
HAART was defined as 1 of the following regimens: у2 nucleoside reverse-transcriptase inhibitors (NRTIs) and at least 1 protease inhibitor (PI) or 1 nonnucleoside reverse-transcriptase inhibitor (NNRTI); у3 NRTIs in a regimen that included abacavir; 1 NRTI and at least 1 PI and at least 1 NNRTI; or 2 PIs and 1 NRTI in a regimen that included ritonavir and saquinavir. The present analysis is based on data for participants who (1) initiated HAART between July 1996 and November 2000, (2) had CD4 + cell count data obtained at the visit immediately prior to HAART initiation, and (3) had at least 1 semiannual visit after HAART initiation. Data on anti-HIV medications used was complete for 99% of the visits by HIVseropositive participants between July 1996 and November 2000. The visit at which the subject first reported having initiated HAART in the prior 6 months was referred to as the "HAART initiation visit." Outcome variables. For each eligible individual, we determined the duration from the HAART initiation visit to the first self-report of each of the 3 risky behaviors of interest (any injection of drugs, needle sharing, and engaging in unprotected sex). All outcome variables were assessed for the 6 months prior to each semiannual visit that occurred after the HAART initiation visit. Although engaging in any sexual intercourse per se is not a high-risk behavior for HIV transmission, it was studied because those engaging in any sexual intercourse represent the group at risk for engaging in unprotected sex. The variable "engaging in any sexual intercourse" was defined as engaging in vaginal, oral, and/or anal sex; "engaging in unprotected sexual intercourse" was defined as engaging in vaginal or anal sex without using a condom; and "needle sharing" was defined as lending, selling, or borrowing needles and injection equipment. Separate analyses were performed for each outcome variable.
Exposure variables. The main exposure variable of interest was the change in the CD4 + cell count from the visit immediately prior to HAART initiation (referred to as the "baseline" visit) to each subsequent visit. We categorized the CD4 + cell count response at each visit according to whether it had increased or not (categorized as increase of 10 cells/mm 3 or of р0 cells/mm 3 ). Change in CD4 + cell count from baseline was treated as a time-dependent variable, and data were lagged by 1 visit to predict behavioral outcomes in the period immediately following that visit. Other variables included in the multivariate analyses were baseline CD4 + cell count at the visit immediately prior to the HAART initiation visit (categorized as count of in the CD4 + cell count and because baseline HIV RNA data were available for only 64% of participants in our study sample.
Statistical analysis. We preformed a retrospective analysis using extended Kaplan-Meier survival analysis [18] to describe the time to the first report of each outcome after HAART initiation. To determine whether change in the CD4 + cell count from baseline was associated with the probability of engaging in the outcome behavior of interest, we used a proportional hazards model with discrete time-to-event methods, using Stata software, version 6 [19] . We initially investigated change in the CD4 + cell count as a categorical variable with 6 categories (decreases of у50 and 0 to 49 cells/mm 3 , and increases of 1-50, 51-100, 101-150, and у150 cells/mm 3 ). In our analysis, however, we determined that a model that dichotomozed changes in CD4 + cell count according to whether there was an increase fit the data equally well, and we report results for this parsimonious model. Durations of follow-up may differ for the analysis of the various outcome variables, because participants are censored in the analysis when they report the behavioral outcome of interest. Those who did not report the respective behavioral outcome during follow-up were censored at their last study visit or at the date of analysis (1 August 2001) . In addition, follow-up visits were included if the visit occurred within 3-9 months after the previous visit; otherwise, the participant was censored at the previous study visit. All CIs were calculated from 2-sided statistical tests, with . a p 0.05
RESULTS
Of 693 HIV-seropositive participants enrolled between July 1996 and November 2000, a total of 276 (40%) initiated HAART during this period. Of these, 49 did not have a visit 3-9 months prior to the HAART initiation visit, 13 had missing baseline CD4 + cell count data, and 24 did not have at least 1 visit after the HAART initiation visit. Therefore, we analyzed data for 190 participants, who represented 69% of the participants who initiated HAART; 71% were male and 29% were female.
At baseline, the median age of enrolled participants was 44 years, the median CD4 + cell count was 260 cells/mm 3 , and the median HIV RNA level was 23,703 copies/mL (table 1). Twenty percent of participants had received a diagnosis of AIDS before initiation of HAART, and 58% initiated HAART after 1997. Baseline demographic, behavioral, immunological, and virological characteristics of the 86 participants excluded from the analysis were similar to those included in the analysis (table  2) . However, those who were included in the analysis were significantly more likely to have initiated HAART after 1997. data for the visit 3-9 months prior to HAART initiation were missing for 49 (57%) of the participants who were excluded from the analysis.
The proportion of participants who engaged in any sexual intercourse, unprotected sex, any drug injection, and/or needle sharing remained stable or increased only slightly from before initiation of HAART to after initiation (any sexual intercourse, 66.3%-71.6% of participants; unprotected sex, 22.9%-26.2%; drug injection, 52.7%-49.0%; needle sharing, 20.0%-26.3%) (figure 1). Although these overall proportions were not significantly different in the pre-HAART and post-HAART periods, there were changes in behaviors at the individual level: although ∼6%-11% of participants discontinued any 1 of the behaviors, ∼7%-14% initiated the respective behaviors after initiating HAART. Approximately 80% of participants continued the behaviors they engaged in before they initiated HAART. Therefore, subsequent survival analyses controlled for pre-HAART behavior to determine factors independently associated with post-HAART behaviors.
Any sexual intercourse. In the analysis of time to first report of any sexual intercourse, ∼35% of HAART initiators had up to 1 year of follow-up, at which time the median CD4 + cell count was ∼30 cells/mm 3 higher than the median baseline CD4 + cell count. At the end of the follow-up, 71.6% of participants reported any sexual intercourse after HAART initiation, 15.4% of whom had not reported any sexual activity in the year prior to HAART initiation. Table 3 shows the results of univariate and multivariate analyses for engaging in sexual intercourse after HAART initiation. In the univariate model, engaging in any sexual intercourse in the 1 year prior to HAART initiation and change in the CD4 + cell count were significantly associated with the increased probability of engaging in any sex after HAART initiation. In the multivariate model, after adjusting for history of sexual activity, increased CD4 + cell count was significantly associated with engaging in any sex after HAART initiation (adjusted relative hazard [ARH], 1.83; 95% CI, 1.22-2.73). We also examined the frequency of sexual intercourse (categorized as once per week or less or more than once per week) after HAART initiation among those engaging in any sex after HAART initiation; however, there was no association between frequency of sex and change in CD4 + cell count. Unprotected sex. In the analysis time to first report of engaging in unprotected sex, almost one-half of the HAART initiators had up to 2 years of follow-up after HAART initiation, at which time the median CD4 + cell count was ∼15 cells/mm 3 higher than the median baseline CD4 + cell count. By the end of follow-up, 26.3% of participants reported having engaged in unprotected sex after HAART initiation, 48.0% of whom had not engaged in unprotected sex in the 1 year prior to HAART initiation. In the univariate model (table 3), we found that engaging in unprotected sex in the year prior to HAART initiation, CD4 + cell count increase, initiation of HAART after 1997, younger age (!45 years), and being female were all significantly associated with the increased probability of having engaged in unprotected sex after HAART initiation. However, after adjusting for past behavior, we found that the following factors remained significantly associated with the hazard of unprotected sex after HAART initiation: CD4 + cell count increase from baseline (ARH, 3.29; 95% CI, 1.57-6.93), AIDS diagnosis prior to HAART initiation (ARH, 2.33; 95% CI, 1.11-4.88), initiation of HAART after 1997 (ARH, 1.94; 95% CI, 1.04-3.63), and younger age (ARH, 0.39, 95% CI, 0.19-0.82). We also examined the change in frequency of condom use (categorized as "always use," "use less than half the time or half the time, "more than half the time," or "never use") from before the initiation of HAART to after initiation. Although the finding was not statistically significant, we found that, of the 50 individuals who reported engaging in unprotected sex after HAART initiation, more of those with increased CD4 + cell counts reported less condom use after HAART initiation than did those with decreased CD4 + cell counts (67.6% vs. 55.6%; data not shown). In addition, although the finding was not statistically significant, decreased condom use after HAART initiation was more common among those with HIV RNA levels of !1500 copies/mL at the previous visit than among those with levels of у1500 copies/mL (71.0% vs. 60.2%).
To further evaluate whether participants engaged in sexual activity, including unprotected sex, after initiating HAART as a result of feeling healthier and more functional, we examined whether participants who had fewer symptoms associated with HIV infection (i.e., fever, fatigue, diarrhea, unexpected weight loss of 14.5 kg, shortness of breath, and thrush) after initiation of HAART were more likely to engage in any sex and in unprotected sex, compared with participants who had more such symptoms after initiation of HAART. No significant differences were found in the probability of engaging in any sex and unprotected sex after HAART initiation (data not shown). Drug injection and needle sharing. At the end of the follow-up, 48.9% of participants reported having injected drugs, 15.1% of whom had not injected drugs in the year prior to HAART initiation; 26.3% reported sharing needles after HAART initiation, 52.0% of whom had not reported sharing needles in the 1 year prior to HAART initiation. In the multivariate models, neither the hazard of injecting drugs nor the hazard of needle sharing were significantly associated with change in the CD4 + cell count from baseline or with baseline CD4 + cell count (data not shown).
DISCUSSION
Although unsafe behaviors such as unprotected sex and needle sharing were reported by approximately one-quarter of HAART initiators, the overall proportion of these participants engaging in these behaviors after HAART initiation increased only modestly. Almost three-quarters of HAART initiators either resumed or continued to engage in sexual activity, and threequarters of these participants reported engaging in protected sex. Although it is encouraging that 20% of participants who injected drugs prior to HAART initiation subsequently stopped injecting drugs, 15% of those who did not inject drugs in th year prior to HAART initiation began injecting drugs after HAART initiation. In additional, although the proportion of HAART initiators injecting drugs remained fairly stable, at 50%, throughout the pre-HAART and post-HAART periods, it remained a high proportion, especially in light of the fact that guidelines for antiretroviral therapy recommend that physicians address substance-abuse problems before prescribing HAART, to improve therapy adherence [20] .
We also examined factors associated with engaging in highrisk behaviors after initiation of HAART. The most predictive factor for each behavioral outcome after initiation of HAART was a history of that behavior. Most important, we found that immunologic improvement after initiation of HAART was associated with sexual-behavior outcomes, but not with drug injection-behavior outcomes. CD4 + cell count increase after HAART initiation was found to be an important predictor of engaging in any sex and engaging in unprotected sex after HAART initiation. This supports findings for HIV-positive homosexual men, among whom it has been reported that improved immunological and virologic outcomes after initiation of HAART are associated with engaging in unprotected sex, decreased concern about infecting sex partners, and the men's belief that they were less infectious [8, 9] . Other studies have reported decreased concern regarding HIV infection and less caution regarding sexual and drug use behaviors because of use of new anti-HIV therapies [10, 11, 13, 21] . Hence, it is possible that the decision of IDUs to engage in high-risk behaviors is influenced by their beliefs regarding anti-HIV treatments, CD4 + cell counts, and HIV RNA levels. Our data indicated that IDUs with increased CD4 + cell counts and lower HIV RNA levels reported using condoms slightly less frequently. Our study participants may have been made aware of their CD4 + cell counts and HIV RNA levels by their HIV/AIDS care providers and/or by the ALIVE clinic staff, and this may have influenced their decisions to engage in high-risk behaviors.
Our data showed no significant difference in the probability of engaging in sex or in unprotected sex after HAART initiation when we compared data for participants who had HIV/AIDSassociated symptoms that decreased after HAART initiation with data for those whose symptoms did not decrease. This may suggest that engaging in any sex and/or in unprotected sex may not be a result of improved clinical health or functional status. However, before reaching this conclusion, it would be important to compare intensity of symptoms, changes in quality of life, and other health status measures.
In this study, drug-related behavioral outcomes were not associated with immunological factors. History of a given behavior was most predictive of engaging in the behavior after initiation of HAART. Longitudinal assessment of drug injection-related behaviors has demonstrated that these behaviors vary over time, and that history of the behavior best predicts current injection and needle sharing behavior [22] .
Our study showed that participants who initiated HAART after 1997 were approximately twice as likely to engage in unprotected sex after initiating HAART. This may be attributed to a bias in HAART initiation, because persons who initiated HAART after 1997 were less immunocompromised and at a greater risk of transmitting the virus as a result of the change in the recommended CD4 + cell count for HAART initiation and possibly because health-care providers have become less stringent about restricting prescription of HAART to IDUs as they have gained more experience with this population [23] . Younger IDUs were also more likely to engage in unprotected sex after HAART initiation. Lastly, we found that receipt of a diagnosis of AIDS prior to HAART initiation was associated with engaging in unprotected sex after HAART initiation. In our study sample, participants who received a diagnosis of AIDS prior to HAART initiation were significantly more likely than those without an AIDS diagnosis to attain an undetectable virus load after HAART initiation (44% vs. 30%), which may explain the increased risk of engaging in unprotected sex after HAART initiation.
Our study has several limitations. First, the analysis is not a comparison of behaviors between subjects who received HAART and subjects who did not. Therefore, we cannot attribute engaging in high-risk behaviors after HAART initiation to receipt of HAART. Second, we were unable to examine whether engaging in unprotected sex and needle sharing occurred between HIV-concordant or HIV-discordant partners, because these behaviors may not be unsafe for monogamous HIV-infected partners. Third, medication use and behaviors were self-reported. However, use of common and prescription names of medications and photographs of the medications should have minimized inaccurate reports of medications used. Moreover, !1% of medication use that was reported by this cohort included drug combinations that were inappropriate because of overlapping toxicity, antagonism, or lack of clinical data [23] . In addition, there is evidence that risk behaviors selfreported by IDUs have high validity [24, 25] .
Despite these limitations, findings from this study indicate that (1) the level of sexual activity, including unprotected sex, is a function of improved immune status after HAART, and (2) drug injection-related behaviors are not influenced by immunological changes. The results of this study indicate the need for education of HIV-seropositive patients who initiate HAART about HIV transmission risk with respect to receipt of antiretroviral therapy. This is particularly important as improved anti-HIV medications become available and more HIV-infected individuals initiate HAART. Providers must counsel patients, not only about health benefits, adherence, and adverse events, but also about the continued importance of safe sexual and drug injection practices.
